Clinical Presentations

In this week's Homerun Slides, the ratios of the adverse events in patients and their tolerability of the placebo vs empagliflozin.

In this week's Homerun Slides, the rate of heart failure hospitalization and all-cause mortality of patients on the placebo vs empagliflozin study.

In this week's Homerun Slides, the cardiovascular outcomes of patients in the placebo vs empagliflozin study.

In this week's Homerun Slides, the vital stats of patients on the placebo and empagliflozin 10- and 25-gram study.

In this week's Homerun Slides, the baseline characteristics of the randomized, placebo-controlled cardiovascular outcome trial of empagliflozin.

In this week's Homerun Slides, EMPA-REG Outcome, examining the long-term effects of empagliflozin versus using a placebo on the heart and mortality risk in patients with type 2.

In this week's Homerun Slides: EMPA-REG Outcome Trial Part 1: Meta-analysis of intensive glucose control in T2DM.

In this week's conclusion of Homerun Slides: Continuous Glucose Monitoring in the Hospital, computerized glucose regulation in the ICU.

In this week's Homerun Slides, blood-based glucose sensors vs. subcutaneous CGM sensors.

In this week's Homerun Slides, the ideal glucose sensor for clinical care.